Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Presidential Memo Reinforces Unfavorable Outlook For PMA Pre-emption

This article was originally published in The Gray Sheet

Executive Summary

A May 20 White House policy statement on pre-emption suggests that if a pending bill to remove protections from state lawsuits for manufacturers of PMA-approved devices passes Congress, there is a good chance the president will sign it into law

You may also be interested in...



Senate Dems Argue That Device Safety Act Will Not Curb Innovation

Senate Democrats are challenging the notion that removing federal pre-emption protection for PMA-approved devices, solidified last year by the Supreme Court, will stifle innovation

Senate Dems Argue That Device Safety Act Will Not Curb Innovation

Senate Democrats are challenging the notion that removing federal pre-emption protection for PMA-approved devices, solidified last year by the Supreme Court, will stifle innovation

Device Industry Groups Lobby Against Bill That Would End PMA Pre-emption

Device industry groups are working to persuade lawmakers that a Supreme Court decision protecting device makers from personal injury suits involving PMA-approved devices should stand

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027483

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel